Terapi Diabetes dengan SGLT-2 Inhibitor
DOI:
https://doi.org/10.55175/cdk.v46i6.442Kata Kunci:
Diabetes, SGLT-inhibitorAbstrak
SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa.
SGLT-2 is a glucose transporter located at renal proximal tubules and responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Unduhan
Referensi
Soelistijo SA, Novia H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia 2015. 1st ed. Jakarta: PB Perkeni; 2015.
American Diabetes Association. Statistics about diabetes. Overall numbers, diabetes and prediabetes [Internet]. 2017 [cited 2017 Oct 13]. Available from: http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.co.id/.
International Diabetes Federation. Diabetes atlas 2017 eight edition [Internet]. 2017 [cited 2018 Oct 07]. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetes-atlas.html.
American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(1):1-135
DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95. doi: 10.2337/db09-9028
Abdul GM, DeFronzo R. Dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2013;14:1695–703
Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63–71
Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice. Diabetes Ther. 2018;9(5):1757–73
Bailey CJ, Day C. SGLT2 inhibitors: Glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis. 2010;10:193-9.
Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther. 2014;5:355-66.
Invokana. FDA highlight of prescribing information. 2016
Farxiga. FDA highlight of prescribing information. 2017
Jardiance. FDA highlight of prescribing information. 2016
Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy. 2014:8 1335–80.
Chen J, Fan F, Xu Y. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: A systematic review and meta-analysis. Sci Rep.2017;7:44128.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–33
Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31
Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med. 2012;156(6):405–15
Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71
Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract. 2013;67(12):1267–82
Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467–77
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
